---
title: "Mirtazapine"
url: https://mghmclean.org/residents/handbk/part2c/mir.htm
description: "· Endocrinologic: Wt. gain, hyperlipidemia, hypercholesteremia."
published: 2026-08-10
updated: 2026-08-10
---

# Mirtazapine

Published 2026-08-10

PART 3 / CH 52

George Papakostas

A. General information

· Contraindicated in patients on MAOI inhibitors.

B. B. Metabolism and phamacokinetics

· Hepatically metabolized.

· Elimination: 85% renal, 15% fecal.

· Need to adjust for both GFR and hepatic impairment

C. Side Effects.

· CNS: Somnolence, Dizziness

· Hematologic: agranulocytosis, incidence 1.1/1000 patients

· Endocrinologic: Wt. gain, hyperlipidemia, hypercholesteremia.

· Gastrointestinal: Transient elevation of LFT’s;

Nausea, dry mouth.

· CV: palpitations, hypotension.